Candidate TB Vaccine Protects TB-Infected Adults Against Active Pulmonary TB

M72/AS01_E candidate tuberculosis vaccine provided 54% protection against active pulmonary TB in HIV-negative adults with latent tuberculosis after a mean follow-up of 2.3 years.

The M72/AS01_E candidate vaccine against tuberculosis (TB) combines two immunogenic Mycobacterium tuberculosis antigens with the AS01 adjuvant system. In phase 2 studies it induced humoral and cell-mediated immune responses in M. tuberculosis-infected adults and bacille Calmette–Guérin (BCG)-vaccinated infants. With partial industry support, investigators have now conducted a double-blind, placebo-controlled phase 2b trial to assess protection against pulmonary TB. At 11 sites in Kenya, South Africa, and Zambia they randomized HIV-negative adults (aged 18–50 years) with latent TB by interferon-γ release assay to receive 2 doses of M72/AS01_E or placebo given intramuscularly 1 month apart.

Follow-up involved active and passive surveillance. Tho…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Candidate TB Vaccine Protects TB-Infected Adults Against Active Pulmonary TB

Topics

Reviewing Author